Literature DB >> 170210

Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA.

G B Clements, G Klein, S Povey.   

Abstract

A continuous lymphoma cell line, BJAB, derived from the tumour of an exceptional African case of Burkitt's lymphoma, has previously been described. Unlike 97% of African BL cases studied, neither the original tumour cells nor the cell line contained detectable amounts of EBV (Epstein-Barr virus) DNA, nor did they express the EBV-determined nuclear antigen EBNA. The cells of the established line had the characteristics of B-type lymphocytes and they carried receptors for EBV. EBNA was induced in the majority of BJAB cells after EBV infection. Usually the cells died within 10 days of infection, but it was possible to establish a permanent EBNA-positive variant (GC-BJAB) of BJAB. The patient from whose tumour the original BJAB line was established was seropositive for EBV antigens, indicating previous exposure to and continuing presence of the virus; yet the tumour had not become infected by EBV. This evidence shows that EBV is not readily "picked up" by the lymphoma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 170210     DOI: 10.1002/ijc.2910160114

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Persistent infection of a human lymphoblastoid cell line with equine herpesvirus 1.

Authors:  L F Roumillat; P M Feorino; P D Lukert
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

2.  Surface marker characteristics and Epstein-Barr virus studies of two established North American Burkitt's lymphoma cell lines.

Authors:  A L Epstein; W Henle; G Henle; J F Hewetson; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1976-01       Impact factor: 11.205

3.  Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.

Authors:  Abhik Saha; Masanao Murakami; Pankaj Kumar; Bharat Bajaj; Karen Sims; Erle S Robertson
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

4.  Integrated viral DNA sequences in Epstein-Barr virus-converted human lymphoma lines.

Authors:  M Andersson-Anvret; T Lindahl
Journal:  J Virol       Date:  1978-03       Impact factor: 5.103

5.  Vaccination against EB virus.

Authors: 
Journal:  Br Med J       Date:  1976-12-18

6.  Initiation points for cellular deoxyribonucleic acid replication in human lymphoid cells converted by Epstein-Barr virus.

Authors:  A Oppenheim; Z Shlomai; H Ben-Bassat
Journal:  Mol Cell Biol       Date:  1981-08       Impact factor: 4.272

7.  Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells.

Authors:  F Wang; A Marchini; E Kieff
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes but not in normal monocytes.

Authors:  J S Gutkind; D C Link; S Katamine; P Lacal; T Miki; T J Ley; K C Robbins
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

9.  Intercellular adhesion molecule-1 expression on human corneal epithelial outgrowth from limbal explant in culture.

Authors:  M Iwata; N Fushimi; Y Suzuki; M Suzuki; T Sakimoto; M Sawa
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

10.  Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.

Authors:  K O Fresen; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.